IN8bio Q2 EPS $(0.19) Misses $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
IN8bio (NASDAQ:INAB) reported Q2 losses of $(0.19) per share, missing the analyst consensus estimate of $(0.17) by 11.76%. This is an improvement from the $(0.27) per share loss in the same period last year.
August 08, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IN8bio reported Q2 losses of $(0.19) per share, missing the analyst consensus estimate of $(0.17) by 11.76%. Despite the miss, the losses have improved from $(0.27) per share in the same period last year.
The miss on the EPS estimate is likely to have a negative short-term impact on the stock price. However, the improvement from last year's losses may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100